feeling lightheaded on tirzepatide Side Effects: Common & Rare Reactions Explained Tirzepatide for Medical Weight Loss

The obesity transition: stages of the global epidemic

The reconstitution calculator can help you find the water volume that produces the cleanest math for your specific dose

We cover the common gastrointestinal effects, the rare but serious risks, the cosmetic concerns like hair loss , and the emerging data on mental health

Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)

10 Women tend to lose more weight than men when using GLP-1 medications